Dienogestrel Powder CAS 65928-58-7 Raw Material

CAS:  65928-58-7 

MF: C20H25NO2

MW: 311.43

EINECS: 639-448-2

Specification​: 99% min Dienogestrel 

Sample: Dienogestrel Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Dienogestrel Powder Usage and Synthesis.

Dienogestrel Powder (dienoest) is a selective luteinizing hormone analog that has been newly marketed in recent years, and can exert a stabilizing effect on endometrial tissue by specifically binding to ethylene nortestosterone and progesterone derivatives. Dienogestrel Powder (dienoest) is a selective luteinizing hormone analog that has been newly marketed in recent years, and can exert a stabilizing effect on endometrial tissue by specifically binding to ethylene nortestosterone and progesterone derivatives.

Some studies have found that tumor necrosis factor (TNF). Some studies have found that tumor necrosis factor (TNF) and interleukin (IL-8) have a tendency to be elevated in patients with endometriosis.

Dienogestrel CAS 65928-58-7 is a hybrid progestin, while Dienogestrel Raw Material has the dual properties of 19-nortestosterone derivatives and progesterone derivatives; therefore, Dienogestrel Raw Material is a hybrid progestin. progesterone derivatives; therefore, it combines both natural and synthetic progestins' uses and functions of Dienogestrel Raw Material. 

Uses and functions of Dienogestrel Powder.

Dienogestrel is a hybrid progestin with the dual properties of 19-nortestosterone derivatives and progesterone derivatives; therefore, it combines both natural and synthetic progestins' Uses and functions of Dienogestrel Powder.

A large randomized, double-blind, placebo-controlled clinical trial conducted by Harada et al. showed that the efficacy of dienogestrel 2mg/d for 24 weeks was comparable to that of buserelin in improving the symptoms of lower abdominal pain, lumbar pain, and pain during sexual intercourse associated with endometriosis, but with a significantly lower rate of adverse effects, such as vaginal bleeding and decreased bone mineral density, and with a better tolerability.

Dienogest is a synthetic contraceptive that belongs to the 19-nortestosterone class of progestins and has strong progestational and antiandrogenic activity. The drug reduces sperm motility by affecting the energy metabolism of sperm. Dienogest was successfully developed by the German company Schering and is used in oral contraception due to its powerful ovulation inhibiting effect. It is becoming the drug of choice for oral contraception because of its efficacy and low toxicity.

Pharmacological Effects of Dienogestrel Powder.

Oral Dienogestrel is completely and rapidly absorbed, with an absolute bioavailability of greater than 90%, reaching maximum serum and plasma concentrations in about 2 and l~2 hours, respectively. In plasma, approximately 10% of dinogestrel is present in the free form, and this proportion of the biologically active fraction is quite high compared to progesterone (0.5-4%). The other 90% of plasma dinogestrel is bound to plasma albumin.

Denogestrel is metabolized primarily by aromatization and 11β-hydroxylation, and the metabolites are rapidly eliminated from the urine within 24 hours of administration. The plasma half-life of dienogest is shorter than that of other progestins, only 6.5~l2 hours, so there is no accumulation of daily administration, which is better than levonorgestrel.

• 1, dienogest is 19-nortestosterone derivatives, does not have androgenic activity, but has anti-androgenic activity, its activity is about one-third of cyproterone acetate. The affinity of Dienogest to bind with human uterine progesterone receptor is only 10% of that of progesterone, although its affinity with progesterone receptor is low, but it has a strong progesterone effect in vivo. Dinogestrel has no obvious androgenic, salocorticoid, glucocorticoid activity in vivo.
• 2. Dinogestrel acts on endometriosis by reducing the endogenous production of estradiol, thereby inhibiting the stimulatory effect of estradiol on the normally located and ectopic endometrium. When administered continuously, dienogestrel results in a low-estrogen, high-progesterone endocrine milieu, which induces metamorphosis of the endometrial tissue, which in turn results in the shrinkage of endometriotic lesions.

Production method of Dienogestrel Powder.